Among them are a series of drugs targeting the nuclear receptor-type transcriptional factors and peroxisome proliferator-activated receptors (PPARs) that have three cognate subtypes (PPARα, PPARδ(/β), PPARγ), and these appear to among the most promising drugs for the treatment of NAFLD/NASH. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.